While B2M and C1qA did not display any change across the spectrum of liver disease, SUCGL1 mRNA expression decreases significantly and progressively with the deterioration of liver disease, reaching the lowest levels in malignant settings, i.e., HCC and CC (Figure 1). This evidence concerns the gene B2M and hepatocellular carcinoma.